RT @uptoTate: Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase…
Tweet Content
Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd
#ACR19 @RheumNow abs#2877
Links
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of…
http://ow.ly/FZuD50x3BOh
Show on Archive Page
On
Display in Search Results
On